| Han, Weidong |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
NCT05693844: Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 15 | RoW | Pan-T booster co-expressing MSLN CAR T cell, Albumin-bound paclitaxel, Cyclophosphamide, Fludarabine | Chinese PLA General Hospital, UTC Therapeutics Inc. | Advanced or Metastatic Solid Tumors | 12/25 | 12/26 | | |
NCT06014073: TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL |
|
|
| Recruiting | 1/2 | 30 | RoW | TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T), Fludarabine, Fludarabine Phosphate for Injection, Cyclophosphamide, Cyclophosphamide for Injection | Chinese PLA General Hospital, Peking University, EdiGene Inc. | Non Hodgkin's Lymphoma | 09/25 | 09/26 | | |
NCT05948033: CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma |
|
|
| Recruiting | 1/2 | 30 | RoW | CD70-targeting CAR-T cells | Chinese PLA General Hospital, UTC Therapeutics Inc. | Lymphoma | 12/25 | 12/26 | | |
NCT05947487: CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 30 | RoW | CD70-targeting CAR-T cells | Chinese PLA General Hospital, UTC Therapeutics Inc. | Solid Tumor, Adult | 12/25 | 12/26 | | |
NCT06079242: Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 200 | RoW | Resin microspheres containing yttrium-90 (Y-90), SIR-Spheres® Y-90 | GrandPharma (China) Co., Ltd. | Colorectal Neoplasms | 12/26 | 04/27 | | |
| Yan, Sheng |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
NCT06560827: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection |
|
|
| Recruiting | 1 | 30 | RoW | CT011 CAR-GPC3 T Cells Injection | CARsgen Therapeutics Co., Ltd., Shanghai Zhongshan Hospital | HCC | 12/26 | 06/27 | | |
